1
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Condition(s):Type 2 Diabetes Mellitus; Impaired Glucose ToleranceLast Updated:September 5, 2011Completed